Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This review examines the roles of macrophages and Langerhans cells in skin homeostasis and suggests that understanding these functions can aid in developing therapies for skin and hair regeneration, but it reports no new research findings.

This study found that alkali bromide solutions are absorbed into hair depending on salt activity, and the presence of the salt increases water absorption compared to normal conditions.

This review discusses scaffold materials and properties used in epidermal tissue engineering to promote skin regeneration and reports no new research findings.

This review discusses the complexities of diagnosing and treating iron deficiency related to nutritional anemia and hair loss, concluding that routine screening and supplementation for hair loss are not yet supported by sufficient evidence.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This review covers the pathophysiology, diagnosis, and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency and reports no new findings.

This review discusses the causes, associated conditions, and treatment options for alopecia areata, such as corticosteroids and wigs, but reports no new clinical findings.

Minoxidil doesn't increase pericardial disorder risk, but may cause fluid accumulation.

This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.

This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.

In this randomized double-blind study, 160 adults with alopecia areata showed significant improvements in hair loss severity after using a bioactive peptide cosmetic product that mimics platelet-rich plasma, while the placebo group showed no significant change, underlining the treatment's potential effectiveness.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

This review discusses the clinical features, genetics, and treatment of 21-hydroxylase deficiency, a common type of congenital adrenal hyperplasia, and reports no new research findings.

This study found that trichoscopy aided in assessing treatment responses for patchy alopecia areata, with both intralesional corticosteroids and platelet-rich plasma showing effectiveness, but only PRP significantly improved patient symptom impact scores.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

This study found that mild-to-moderate COVID-19 was not associated with worsening in patients with pre-existing alopecia areata.

This study found that flumethasone administration in Merino wethers led to variations in wool shedding and initial reductions in wool growth, with full recovery generally observed within 60 days post-treatment.

This study found that both topical calcipotriol and narrow band ultraviolet B phototherapy improved hair regrowth and vitamin D3 levels in alopecia areata patients.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.

This review addresses alopecia areata, emphasizing its autoimmune nature, unpredictable course, and lack of preventive or curative treatments, while noting standard and emerging therapies such as topical steroids and Janus kinase inhibitors.

This study found that individualized homeopathic medicine can significantly improve outcomes in patients with alopecia areata, including complete hair regrowth and reduced SALT scores within 5 to 12 months, without relapse, and shows promise for alopecia universalis through targeted miasmatic and constitutional remedies.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This study found that combining topical calcipotriol with intralesional autologous PRP injection significantly reduced Severity of Alopecia Tool scores in patients with alopecia areata, more effectively than either treatment alone.

This study found that patients with alopecia areata had significantly lower serum 25-Hydroxy vitamin D levels compared to healthy controls, and observed a significant inverse relationship between vitamin D levels and disease severity.

This study found that human placental extract significantly improved melasma, chronic ulcers, and alopecia areata without major adverse effects, suggesting its effectiveness and safety for these conditions.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.